Figure 5. TCN and gemcitabine treatment decreases Akt activity and proliferation rate in vivo.

(A) pAkt 473 levels were assayed in both wtFKBP5 and shFKBP5 tumor tissues. ***P<0.005. (B and C) Tumor samples from wtFKBP5 SU86 and shFKBP5 SU86 xenografts were prepared and stained for Ki67. (D) Quantification of Ki67 staining was expressed as percentage of positive cells (5 random fields for each sample, ***P<0.05). Statistical evaluation was performed with t test.